William J. Caragol, PositiveID’s Chairman and CEO, called in to SmallCapVoice.com from his meetings in New York City to provide the listeners and the PSID shareholders with further insights to the recently announced and first-ever revenue guidance of $4-10 million over the next 18 months, $3.3 million of which is already in backlog.
[3:10:34 PM] Stuart Smith: About M-BAND
PositiveID’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) continuously and autonomously analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins. The technology was developed under contract with the U.S. Department of Homeland Security (“DHS”) Science & Technology directorate, which included $30 million of contract funding, to detect an attack with a biological weapon.
PositiveID’s Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results from a sample in less than 20 minutes at the point of need, compared to two to four hours for a lab device, using real-time TaqMan(R) PCR (polymerase chain reaction) chemistry. Firefly is being developed to meet the growing need for more rapid and accurate point-of-need diagnostics that will enable hospitals, first responders, and other providers to save lives.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.